Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)

References

• Kuzuki T, Perry B, Mowbray C. NTD drug discovery booster, achievements and next steps. Yakugaku Zasshi. 2022;142(7):685–689.
   PubMed Web of Science ®Google Scholar
• WHO, 2022 https://www.who.int/health-topics/leishmaniasis#tab=tab_1
   Google Scholar
• Volpedo G, Huston RH, Holcomb EA, et al. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection. Expert Rev Vaccines. 2021;20(11):1431–1446. DOI:10.1080/14760584.2021.1969231
   PubMed Web of Science ®Google Scholar
• Kaye P, Scott P. Leishmaniasis: complexity at the host–pathogen interface. Nat Rev Microbiol. 2011;9(8):604–615.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012;26(2):309–322.
   PubMed Web of Science ®Google Scholar
• Lindoso JAL, Moreira CHV, Cunha MA, et al. Visceral leishmaniasis and HIV coinfection: current perspectives. HIV AIDS (Auckl). 15 2018;10: 193–201. DOI:10.2147/HIV.S143929
   PubMedGoogle Scholar
• Sundar S, Chakravarty J. Visceral leishmaniasis. Ponte-Sucre A, Padrón-Nieves M, editors. Cham (Switzerland): Springer; 2018. p. 159–176.
   Google Scholar
• Alvar J, Vélez ID, Bern C, et al. WHO leishmaniasis control team. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671. DOI:10.1371/journal.pone.0035671
   PubMed Web of Science ®Google Scholar
• Mokni M. Leishmanioses cutanées [Cutaneous leishmaniasis]. Ann Dermatol Venereol. 2019;146(3):232–246.
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7(7):581–596. DOI:10.1016/S1473-3099(07)70209-8
   PubMedGoogle Scholar
• Gabriel Á, Valério-Bolas A, Palma-Marques J, et al. Cutaneous leishmaniasis: the complexity of host’s effective immune response against a polymorphic parasitic disease. J Immunol Res. 2019;2603730:1–16.
   Google Scholar
• Strazzulla A, Cocuzza S, Pinzone MR, et al. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. BioMed Res Int. 2013;2013:1–7.
   Web of Science ®Google Scholar
• Abadías-Granado I, Diago A, Cerro PA, et al. Leishmaniasis cutánea y mucocutánea. Actas Dermo-Sifiliográficas. 2021;112(7):601–618. DOI:10.1016/j.ad.2021.02.008
   Google Scholar
• Stamm LV. Human migration and leishmaniasis-on the move. JAMA Dermatol. 2016;152(4):373–374.
   PubMed Web of Science ®Google Scholar
• Channon JY, Roberts MB, Blackwell JM. A study of the differential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages. Immunology. 1984;53(2):345–355.
   PubMed Web of Science ®Google Scholar
• McConville MJ, de Souza D, Saunders E, et al. Living in a phagolysosome; metabolism of Leishmania amastigotes. Trends Parasitol. 2007;23(8):368–375. DOI:10.1016/j.pt.2007.06.009
   PubMed Web of Science ®Google Scholar
• Fidalgo LM, Gille L. Mitochondria and trypanosomatids: targets and drugs. Pharm Res. 2011;28(11):2758–2770.
   PubMed Web of Science ®Google Scholar
• Desjeux P. Prevention of Leishmania donovani infection. BMJ. 2010;29(341):c6751.
   Google Scholar
• Handler MZ, Patel PA, Kapila R, et al. Cutaneous and mucocutaneous Leishmaniasis: clinical perspectives. J Am Acad Dermatol. 2015;73(6):897–908. DOI:10.1016/j.jaad.2014.08.051
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Control of leishmaniasis: report of a meeting of the WHO expert committee on the control of Leishmaniases, geneva. Geneva: World Health Organ; 2010.
   Google Scholar
• Losada-Barragán M, Umaña-Pérez A, Durães J, et al. Thymic microenvironment is modified by malnutrition and Leishmania infantum infection. Front Cell Infect Microbiol. 12 2019;9: 252.doi: 10.3389/fcimb.2019.00252
   PubMed Web of Science ®Google Scholar
• Nylén S, Eidsmo L. Tissue damage and immunity in cutaneous Leishmaniasis. Parasite Immunol. 2012;34(12):551–561.
   PubMed Web of Science ®Google Scholar
• Rojas R, Valderama L, Valderama M, et al. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis. 2006;193(10):1375–1383. DOI:10.1086/503371
   PubMed Web of Science ®Google Scholar
• Hohman LS, Peters NC. CD4+ T cell-mediated immunity against the phagosomal pathogen Leishmania: implications for Vaccination. Trends Parasitol. 2019;35(6):423–435.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinto D, Saravia NG, McMahon-Pratt D. CD4 T cell activation by B cells in human Leishmania (Viannia) infection. BMC Infect Dis. 2014;14(1):108. 25. DOI:10.1186/1471-2334-14-108
   PubMedGoogle Scholar
• Kedzierski L, Sakthianandeswaren A, Curtis JM, et al. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem. 2009;16(5):599–614. DOI:10.2174/092986709787458489
   PubMed Web of Science ®Google Scholar
• Soni M, Pratap JV. Development of novel anti-leishmanials: the case for structure-based approaches. Pathogens. 2022;11(8):950. 22. DOI:10.3390/pathogens11080950
   PubMed Web of Science ®Google Scholar
• Briggs N, Wei BM, Ahuja C, et al. Mucocutaneous Leishmaniasis in a pregnant immigrant. Open Forum Infect Dis. 2022;9(8):ofac360. 22. DOI:10.1093/ofid/ofac360
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, López-Vélez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis. 2015;60(9):1398–1404. 1. DOI:10.1093/cid/civ004
   PubMed Web of Science ®Google Scholar
• Amato V, Amato J, Nicodemo A, et al. Traitement par iséthionate de pentamidine de la leishmaniose muqueuse [Treatment of mucocutaneous leishmaniasis with pentamidine isothionate]. Ann Dermatol Venereol. 1998;125(8):492–495.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008;17(5):787–794.
   PubMed Web of Science ®Google Scholar
• Conceição-Silva F, Leite-Silva J, Morgado FN. The binomial parasite-host immunity in the healing process and in reactivation of human tegumentary Leishmaniasis. Front Microbiol. 2018;9:1308. 19. DOI:10.3389/fmicb.2018.01308
   PubMed Web of Science ®Google Scholar
• Kumar VU, Kt MF, Sharma A, et al. The possible role of selected vitamins and minerals in the therapeutic outcomes of Leishmaniasis. Biol Trace Elem Res. 2023;2(4):1672–1688. Epub ahead of print. 2022. DOI:10.1007/s12011-022-03311-6
   Google Scholar
• Galvão EL, Pedras MJ, Cota GF, et al. How cutaneous leishmaniasis and treatment impacts patients’ lives: a cross-sectional study. PLoS ONE. 2019;14(1):e0211374. 25. DOI:10.1371/journal.pone.0211374
   PubMed Web of Science ®Google Scholar
• dos Santos Ferreira C, Martins PS, Demicheli C, et al. Thiol-induced reduction of antimony (V) into antimony (III): a comparative study with trypanothione, cysteinyl-glycine, cysteine, and glutathione. Biometals. 2003;16(3):441–446. DOI:10.1023/A:1022823605068
   PubMed Web of Science ®Google Scholar
• Matoussi N, Ameur HB, Amor SB, et al. Toxicité cardiaque de l’antimoniate de méglumine (Glucantime). A propos d’une observation [Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report]. Med Mal Infect. 2007;37(3):S257–9. DOI:10.1016/j.medmal.2007.08.001
   PubMedGoogle Scholar
• Veiga JP, Wolff ER, Sampaio RN, et al. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet. 1983;2(8349):569. 3. DOI:10.1016/S0140-6736(83)90595-0
   PubMed Web of Science ®Google Scholar
• Maristany Bosch M, Cuervo G, Matas Martín E, et al. Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis. Clin Neurophysiol Pract. 25 2021;6: 164–167. DOI:10.1016/j.cnp.2021.03.008
   PubMedGoogle Scholar
• Kato KC, Morais-Teixeira E, Reis PG, et al. Hepatotoxicity of the pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid. Antimicrob Agents Chemother. 2014;58(1):481–488. DOI:10.1128/AAC.01499-13
   PubMed Web of Science ®Google Scholar
• Liu M, Chen M, Yang Z. Design of amphotericin B oral formulation for antifungal therapy. Drug Deliv. 2017;24(1):1–9.
   PubMed Web of Science ®Google Scholar
• Stone NR, Bicanic T, Salim R, et al. Liposomal Amphotericin B (AmBisome(®)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485–500.
   PubMed Web of Science ®Google Scholar
• Brajtburg J, Powderly WG, Kobayashi GS, et al. Amphotericin B: delivery system. Antimicrob Agents Chemother. 1990;34(3):381–384. DOI:10.1128/AAC.34.3.381
   PubMed Web of Science ®Google Scholar
• Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990;5(2):94–108.
   PubMed Web of Science ®Google Scholar
• Kaminsky R. Miltefosine Zentaris. Curr Opin Invest Drugs. 2002;3(4):550–554.
   PubMedGoogle Scholar
• Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother. 2005 Jul;6(8):1381–1388.
   PubMed Web of Science ®Google Scholar
• ZENTARIS AG: impavido registration certificate for Miltefosine capsules 10 mg and 50 mg. Issued by Drug Controller General India. 2002.
   Google Scholar
• ZENTARIS AG: impavido registration certificate for Miltefosine capsules 10 mg and 50 mg. Issued by German Registration Authority. 2004.
   Google Scholar
• Santos Nogueira F D, Avino VC, Galvis-Ovallos F, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasites Vectors. 2019;12(1):79. 8. DOI:10.1186/s13071-019-3323-0
   PubMedGoogle Scholar
• Verma NK, Singh G, Dey CS. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp Parasitol. 2007;116(1):1–13.
   PubMed Web of Science ®Google Scholar
• Schlossberg D, Samuel R. Miltefosine (Impavido, Miltex). Antibiot manual a Guid to commonly used anti-microbialsp. 287–288, 2011.
   Google Scholar
• Singh G, Dey CS. Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovani. Acta Trop. 2007;103(3):172–185.
   PubMed Web of Science ®Google Scholar
• Basselin M, Lawrence F, Robert-Gero M. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem J. 1996;15(2):315.
   Google Scholar
• Naafs B. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg. 1985;79(1):141.
   PubMed Web of Science ®Google Scholar
• Kanyok TP, Reddy MV, Chinnaswamy J, et al. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother. 1994;38(2):170–173. DOI:10.1128/AAC.38.2.170
   PubMed Web of Science ®Google Scholar
• Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg. 2009;103(7):653–660.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571–2581. DOI:10.1056/NEJMoa066536
   PubMed Web of Science ®Google Scholar
• Kasabalis D, Chatzis MK, Apostolidis K, et al. Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: a randomized, blinded, controlled study. Exp Parasitol. 2019;206:107768.
   PubMed Web of Science ®Google Scholar
• Letzring DP, Wolf AS, Brule CE, et al. Translation of CGA codon repeats in yeast involves quality control components and ribosomal protein L1. RNA. 2013;9(9):1208–1217. DOI:10.1261/rna.039446.113
   Google Scholar
• Verrest L, Wasunna M, Kokwaro G, et al. Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. Clin Pharmacokinet. 2021;60(11):1463–1473. DOI:10.1007/s40262-021-01036-8
   PubMed Web of Science ®Google Scholar
• White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 1999;41(1–3):301–308.
   PubMedGoogle Scholar
• Maldonado V, Loza-Mejía MA, Chávez-Alderete J. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. Med Hypotheses. 2020;144:109988.
   PubMed Web of Science ®Google Scholar
• Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg. 2001;65(2):87–89. DOI:10.4269/ajtmh.2001.65.87
   PubMed Web of Science ®Google Scholar
• Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, et al. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol. 2013;69(5):1057–1073. DOI:10.1007/s00228-012-1452-x
   PubMed Web of Science ®Google Scholar
• Cincura C, Costa RS, De Lima CMF, et al. Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline. Trop Med Infect Dis. 2022;7(11):383. 16. DOI:10.3390/tropicalmed7110383
   PubMedGoogle Scholar
• Brito G, Dourado M, Guimarães LH, et al. Oral Pentoxifylline Associated with Pentavalent Antimony: a Randomized Trial for Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2017;96(5):1155–1159. DOI:10.4269/ajtmh.16-0435
   PubMed Web of Science ®Google Scholar
• Castro MDM, Cossio A, Navas A, et al. Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: a Randomized Clinical Trial in Colombia. Pathogens. 2022;11(3):378. 21. DOI:10.3390/pathogens11030378
   PubMed Web of Science ®Google Scholar
• Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother. 2006;50(1):73–79.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2000;94(4):429–431. DOI:10.1016/S0035-9203(00)90130-5
   PubMed Web of Science ®Google Scholar
• Parvez S, Yadagiri G, Gedda MR, et al. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep. 2020;10(1):12243. DOI:10.1038/s41598-020-69276-5
   PubMed Web of Science ®Google Scholar
• Lee H, Baek KH, Phan TN, et al. Discovery of Leishmania donovani topoisomerase IB selective inhibitors by targeting protein-protein interactions between the large and small subunits. Biochem Biophys Res Commun. 2021;569:193–198.
   PubMed Web of Science ®Google Scholar
• Marquis JF, Drolet M, Olivier M. Consequence of Hoechst 33342-mediated Leishmania DNA topoisomerase-I inhibition on parasite replication. Parasitology. 2003;26(1):21–30.
   Google Scholar
• Singh G, Jayanarayan KG, Dey CS. Novobiocin induces apoptosis-like cell death in topoisomerase II over-expressing arsenite-resistant Leishmania donovani. Mol Biochem Parasitol. 2005;141(1):57–65.
   PubMed Web of Science ®Google Scholar
• Feng M, Jin Y, Yang S, et al. Sterol profiling of Leishmania parasites using a new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway. Int J Parasitol Drugs Drug Resist. 2022;20:27–42.
   PubMed Web of Science ®Google Scholar
• Wadanambi PM, Mannapperuma U. Computational study to discover potent phytochemical inhibitors against drug target, squalene synthase from Leishmania donovani. Heliyon. 2021;7(6):e07178.
   PubMed Web of Science ®Google Scholar
• Leroux AE, Krauth-Siegel RL. Thiol redox biology of trypanosomatids and potential targets for chemotherapy. Mol Biochem Parasitol. 2016;206(1–2):67–74.
   PubMed Web of Science ®Google Scholar
• Wanasen N, Soong L. L-arginine metabolism and its impact on host immunity against Leishmania infection. Immunol Res. 2008;41(1):15–25.
   PubMed Web of Science ®Google Scholar
• da Silva ER, Maquiaveli Cdo C, Magalhães PP. The leishmanicidal flavonols quercetin and quercitrin target Leishmania (Leishmania) amazonensis arginase. Exp Parasitol. 2012;130(3):183–188.
   PubMed Web of Science ®Google Scholar
• da Silva ER, Boechat N, Pinheiro LC, et al. Novel selective inhibitor of Leishmania (Leishmania) amazonensis arginase. Chem Biol Drug Des. 2015;86(5):969–978. DOI:10.1111/cbdd.12566
   PubMed Web of Science ®Google Scholar
• Perry MR, Prajapati VK, Menten J, et al. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study. PLoS Negl Trop Dis. 2015;9(3):e0003518. DOI:10.1371/journal.pntd.0003518
   PubMed Web of Science ®Google Scholar
• Légaré D, Richard D, Mukhopadhyay R, et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem. 2001;276(28):26301±7. DOI:10.1074/jbc.M102351200
   PubMed Web of Science ®Google Scholar
• Mandal G, Mandal S, Sharma M, et al. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1. PLoS Negl Trop Dis. 2015;9(2):e0003500. DOI:10.1371/journal.pntd.0003500
   PubMed Web of Science ®Google Scholar
• Nateghi-Rostami M, Tasbihi M, Darzi F. Involvement of tryparedoxin peroxidase (TryP) and trypanothione reductase (TryR) in antimony unresponsive of Leishmania tropica clinical isolates of Iran. Acta Trop. 2022;230:106392.
   PubMed Web of Science ®Google Scholar
• Singh J, Khan MI, Singh Yadav SP, et al. L-Asparaginase of Leishmania donovani: metabolic target and its role in Amphotericin B resistance. Int J Parasitol Drugs Drug Resist. 2017;7(3):337–349. DOI:10.1016/j.ijpddr.2017.09.003
   PubMed Web of Science ®Google Scholar
• Rebello KM, Andrade-Neto VV, Gomes CRB, et al. Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: in vitro and in vivo Approaches. Front Cell Infect Microbiol. 28 28 2019;9: 229. DOI:10.3389/fcimb.2019.00229
   PubMed Web of Science ®Google Scholar
• Roatt BM, de Oliveira Cardoso JM, De Brito RCF, et al. Recent advances and new strategies on leishmaniasis treatment. Appl Microbiol Biotechnol. 2020;21(21):8965–8977. DOI:10.1007/s00253-020-10856-w
   Google Scholar
• Ahmed H, Curtis CR, Tur-Gracia S, et al. Drug combinations as effective anti-leishmanials against drug resistant Leishmania mexicana. RSC Med Chem. 2020;11(8):905–912. DOI:10.1039/D0MD00101E
   PubMedGoogle Scholar
• Andrade-Neto VV, Rebello KM, Pereira TM, et al. Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis. Antimicrob Agents Chemother. 2021;65(5): e02676-20. DOI:10.1128/AAC.02676-20
   PubMed Web of Science ®Google Scholar
• Yang YH, Buttery J. Antimicrobial resistance: a global one-health problem for all ages. World J Pediatr. 2018;6(6):521–522.
   Google Scholar
• Handman E. Cell biology of Leishmania. Adv Parasitol. 1999;44:1–39.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay R, Dey S, Xu N, et al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci U S A. 1996;93(19):10383–10387. DOI:10.1073/pnas.93.19.10383
   PubMed Web of Science ®Google Scholar
• García-Hernández R, Manzano JI, Castanys S, et al. Leishmania donovani develops resistance to drug combinations. PLoS Negl Trop Dis. 2012;6(12):e1974. DOI:10.1371/journal.pntd.0001974
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Padmanabhan PK, Sahani MH, et al. Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol Biochem Parasitol. 2006;145(1):1–10. DOI:10.1016/j.molbiopara.2005.08.016
   PubMed Web of Science ®Google Scholar
• Whatmore RW. Nanotechnology—what is it? Should we be worried? Occup Med. 2006;56(5):295–299.
   Google Scholar
• Heath JR. Nanotechnologies for biomedical science and translational medicine. Proc Natl Acad Sci. 2015;112(47):14436–14443.
   PubMed Web of Science ®Google Scholar
• Kumar N, Kumbhat S. Essentials in Nanoscience and Nanotechnology, 1st ed ed. Hoboken (USA): Wiley, 2016:p. 326–360. Chapter 8, Unique properties.
   Google Scholar
• Stark WJ, Stoessel PR, Wohlleben, et al. A Industrial applications of nanoparticles. Chem Soc Rev. 2014;46(38).
   Google Scholar
• Jamshaid H, Ud DF, Khan GM. Nanotechnology-based solutions for anti-leishmanial impediments: a detailed insight. J Nanobiotechnology. 2021;19(1):1–51.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. DOI:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Salata OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnology. 2004;6:1–6.
   Google Scholar
• Thomas TC, Acuña-Narvaez R. The convergence of biotechnology and nanotechnology: why here, why now? J Commer Biotechnol. 2006;12(2):105–110.
   Google Scholar
• Kirtane AR, Verma M, Karandikar P, et al. Nanotechnology approaches for global infectious diseases. Nat Nanotechnol. 2021;16(4):369–384. DOI:10.1038/s41565-021-00866-8
   PubMed Web of Science ®Google Scholar
• Joshi G, Quadir SS, Yadav KS. Road map to the treatment of neglected tropical diseases: nanocarriers interventions. J Control Release. 2021;339:51–74.
   PubMed Web of Science ®Google Scholar
• Pandian SRK, Panneerselvam T, Pavadai P, et al. Nano Based Approach for the Treatment of Neglected Tropical Diseases. Front Nanotechnol. 2021;3(3):1–21. DOI:10.3389/fnano.2021.665274
   Google Scholar
• Zhang B, Chen J, Cao Y, et al. Ligand Design in Ligand-Protected Gold Nanoclusters. Small. 2021 Jul;17(27):e2004381.
   PubMed Web of Science ®Google Scholar
• Benelli G. Gold nanoparticles – against parasites and insect vectors. Acta Trop. 2018;178:73–80.
   PubMed Web of Science ®Google Scholar
• Saleem K, Khursheed Z, Hano C, et al. Applications of Nanomaterials in Leishmaniasis: a Focus on Recent Advances and Challenges. Nanomaterials. 2019;9(12):1749. DOI:10.3390/nano9121749
   Web of Science ®Google Scholar
• Smith L, Serrano DR, Mauger M, et al. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis. Mol Pharm. 2018;15(7):2570–2583. DOI:10.1021/acs.molpharmaceut.8b00097
   PubMed Web of Science ®Google Scholar
• El-Khadragy M, Alolayan EM, Metwally DM, et al. Clinical Efficacy Associated with Enhanced Antioxidant Enzyme Activities of Silver Nanoparticles Biosynthesized Using Moringa oleifera Leaf Extract, Against Cutaneous Leishmaniasis in a Murine Model of Leishmania major. Int J Environ Res Public Health. 2018;15(5):1037. DOI:10.3390/ijerph15051037
   PubMed Web of Science ®Google Scholar
• Ahmad A, Wei Y, Syed F, et al. Isatis tinctoria mediated synthesis of amphotericin B-bound silver nanoparticles with enhanced photoinduced antileishmanial activity: a novel green approach. J Photochem Photobiol B. 2016;161:17–24.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Wei Y, Ullah S, et al. Synthesis of phytochemicals-stabilized gold nanoparticles and their biological activities against bacteria and Leishmania. Microb Pathog. 2017;110:304–312.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Ullah S, Syed F, et al. Biogenic metal nanoparticles as a potential class of antileishmanial agents: mechanisms and molecular targets. Nanomedicine (Lond). 2020;15(8):809–828. DOI:10.2217/nnm-2019-0413
   PubMed Web of Science ®Google Scholar
• Albalawi AE, Alanazi AD, Sharifi I, et al. A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents. Acta Parasitol. 2021 Sep;66(3):797–811.
   PubMed Web of Science ®Google Scholar
• Tiwari B, Pahuja R, Kumar P, et al. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis. Antimicrob Agents Chemother. 2017;61(3): 23 23. DOI:10.1128/AAC.01169-16
   Web of Science ®Google Scholar
• Fattahi Bafghi A, Haghirosadat BF, Yazdian F, et al. A novel delivery of curcumin by the efficient nanoliposomal approach against Leishmania major. Prep Biochem Biotechnol. 2021;51(10):990–997. DOI:10.1080/10826068.2021.1885045
   PubMed Web of Science ®Google Scholar
• Tang H, Ye H, Zhang H, et al. Aggregation of nanoparticles regulated by mechanical properties of the nanoparticle-membrane system. Nanotechnology. 2018;29(40):405102. DOI:10.1088/1361-6528/aad443
   PubMed Web of Science ®Google Scholar
• Laradji M, Kumar PBS, Spangler EJ. Adhesion and Aggregation of Spherical Nanoparticles on Lipid Membranes. Chem Phys Lipids. 2020;233:104989.
   PubMed Web of Science ®Google Scholar
• Lavagna E, Barnoud J, Rossi G, et al. Size-dependent aggregation of hydrophobic nanoparticles in lipid membranes. Nanoscale. 2020;12(17):9452–9461. DOI:10.1039/D0NR00868K
   PubMed Web of Science ®Google Scholar
• Singh A, Yadagiri G, Negi M, et al. Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system. Int j biol macromol. 2022;04:373–385.
   Google Scholar
• Mahmoudi M. The need for improved methodology in protein corona analysis. Nat Commun. 2022;13(1):1–4.
   PubMedGoogle Scholar
• Tekie FSM, Hajiramezanali M, Geramifar P, et al. Controlling evolution of protein corona: a prosperous approach to improve chitosan-based nanoparticle biodistribution and half-life. Sci Rep. 2020;10(1):1–14. DOI:10.1038/s41598-020-66572-y
   PubMed Web of Science ®Google Scholar
• Sacchetti C, Motamedchaboki K, Magrini A, et al. Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano. 2013;7(3):1974–1989. DOI:10.1021/nn400409h
   PubMed Web of Science ®Google Scholar
• Sanchez-Moreno P, Buzon P, Boulaiz H, et al. Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. Biomaterials. 2015;61:266–278.
   PubMed Web of Science ®Google Scholar
• Peng M, Li H, Luo Z, et al. Dextran-coated superparamagnetic nanoparticles as potential cancer drug carriers in vivo. Nanoscale. 2015;7(25):11155–11162. DOI:10.1039/C5NR01382H
   PubMed Web of Science ®Google Scholar
• Natte K, Friedrich JF, Wohlrab S, et al. Impact of polymer shell on the formation and time evolution of nanoparticle–protein corona. Colloids Surf B Biointerfaces. 2013;104:213–220.
   PubMed Web of Science ®Google Scholar
• Mohammad-Beigi H, Hayashi Y, Zeuthen CM, et al. Mapping and identification of soft corona proteins at nanoparticles and their impact on cellular association. Nat Commun. 2020;11(1):1–16. DOI:10.1038/s41467-020-18237-7
   PubMed Web of Science ®Google Scholar
• Domenico B, Donato C, Massimo F, et al., Inventors; Universita Degli Studi Magna Graecia di Catanzaro, assignee. Nanoparticulate systems for vehiculating drugs for the treatment of leishmania infection-related pathologies. PCT patent WO2015/177820. 2015.
   Google Scholar
• Sanyog J, Kaushik T, inventors; National Institute Of Pharmaceutical Education & Research, assignee. Novel lipid drug conjugates for improved oral delivery of amphotericin b and nanoformulations thereof. India patent IN2015DE01450. 2016.
   Google Scholar
• Neena G, Sonali G, Kala SAK, et al., inventors; Council of Scientific & Industrial Research, Assignee. A novel antileishmanial formulation. India patent IN2015DE00125. 2016.
   Google Scholar
• Neena G, Sonali G, Kala SAK, et al., inventors; Council of Scientific & Industrial Research, assignee. A novel antileishmanial formulation. PCT patent WO2016113763. 2016.
   Google Scholar
• Kawthar B, Christian B, Philippe L, et al., inventors; Centre National De La Recherche Scientifique, Universite Paris Saclay, assignees. Antiparasitic and/or antifungal composition comprising hydrophobized chitosan. United States patent US10172947. 2019.
   Google Scholar
• Kawthar B, Christian B, Philippe L, et al., inventors; Centre National De La Recherche Scientifique, Universite Paris Saclay, assignees. Antiparasitic and/or antifungal composition comprising hydrophobized chitosan. United States patent US20160243243. 2016.
   Google Scholar
• Faraco AAG, Coelho EAF, Franca JR, et al., inventors; Universidade Federal De Minas Gerais, assignee. Uso de nanopartículas de quitosana e condroitina para o tratamento de leishmaniose. Brazil patent BR102013017881. 2020 Mar 4.
   Google Scholar
• Moreira ACOM, da Costa FN, Moreira RA, inventors; Fundação Edson Queiroz, assignee. Processo de obtenção e uso de nanopartícula a base de hemicelulose contendo óleos essenciais com atividade antiparasitária em doenças negligenciadas. Brazil patent BR102014031328. 2021.
   Google Scholar
• Bharat PV, Anilbhai PP, inventors. Lipidic nanoparticles based composition and method of formulation and use thereof. India patent IN279598. 2017.
   Google Scholar
• Satoskar AR, Fuchs JF, Kinghorn AD, et al., inventors; Ohio State Innovation Foundation, assignee. Antileishmanial compositions and methods of use. United States patent US10174072. 2019.
   Google Scholar
• Satoskar AR, Fuchs JF, Kinghorn AD, et al., inventors; Ohio State Innovation Foundation, assignee. Antileishmanial compositions and methods of use. United States patent US20170305959. 2017.
   Google Scholar
• Madhusudan B, Ranjan MA, Susmita M, et al., inventors; All India Institute of Medical Sciences, assignee. Novel nanocarrier for efficient drug delivery. India patent IN201611009768. 2018.
   Google Scholar
• Soumyajit M, Akash P, Prit P, inventors; University of Mississippi, assignee. Amphotericin Loaded Pegylated Lipid Nanoparticles and Methods of Use. United States patent US20210330598. 2021.
   Google Scholar
• Chandradhish G, Peter S, inventors; Max Planck Institute, assignee. Amphotericin B conjugated stabilized gold nanoparticles and uses thereof. PCT patent WO2021/116475. 2021.
   Google Scholar
• Chandradhish G, Peter S, inventors; Max Planck Institute, assignee. Amphotericin B conjugated stabilized gold nanoparticles and uses thereof. Europe Patent Office EP3834848. 2021.
   Google Scholar
• WIPO [Internet]. Geneva, Switzerland: world Intellectual Property; c1967-2022. Patenting Nanotechnology: exploring the Challenges; 2011 Apr [cited 2022 Dec 13]; [about 7 screens]. Available from: https://www.wipo.int/wipo_magazine/en/2011/02/article_0009.html
   Google Scholar
• Peters P Mind the gap: spanning the divide between patents and journal articles [Internet]. 2019 Feb 1 [cited 2022 Dec 13]. Available from: https://www.cas.org/resources/blog/mind-gap-spanning-divide-between-patents-and-journal-articles
   Google Scholar